Medtronic, a global leader in healthcare technology, today announced that four of its technologies have received Japan’s 2025 Good Design Award, a comprehensive national recognition for design excellence. This is the first year that four Medtronic technologies have received the award.

The 2025 Medtronic Good Design Award winning solutions are:

• PROPEL™ Sinus Implant – Japan’s first bioabsorbable, steroid-eluting sinus implant that supports postoperative healing and reduces recurrence risk following sinus surgery.
• Aurora EV-ICD™ MRI System – First-of-its-kind extravascular ICD system, designed to reduce procedural risk and improve patient comfort by eliminating the need for transvenous leads, instead positioning the Epsila™ EV MRI lead beneath the sternum.
• Onyx Frontier™ Coronary Stent – A next-generation stent delivery system that combines increased catheter flexibility and deliverability, and a lower crossing profile to treat complex coronary lesions.  Onyx Frontier offers a broad size matrix, including Japan’s smallest 2.0 mm stent for small vessels.
• Evolut™ FX+ Transcatheter Aortic Valve Replacement (TAVR) System – An enhanced frame design with addition of larger windows to facilitate coronary access to leverage market-leading valve performance.

Organized by the Japan Institute of Design Promotion, the annual Good Design Award recognizes a variety of products based on efficacy, utility, and potential to enrich both individual lives and society at large.

The Good Design Award jury recognized all four Medtronic technologies for their combination of technical innovation, clinical impact, and human-centered design. Each product was praised for addressing complex medical challenges through thoughtful engineering that improves quality of care and patient outcomes.

About the Good Design Award
Established in 1957, the Good Design Award is Japan’s leading program for the comprehensive evaluation and promotion of design, succeeding the original Good Design Selection System.  Recognized globally, the award attracts participation from numerous companies and organizations both in Japan and overseas.  Held annually, it aims to enhance the quality of life and leverage the power of design to address social challenges and emerging themes.  The symbol of the award, the “G Mark,” is widely recognized as a mark of excellence in design. Visit www.g-mark.org.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Marie Gentile
Public Relations
+1-404-693-6028

Ryan Weispfenning
Investor Relations
+1-763-505-4626